• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Wait a Few Days to Trade Vertex So You Don't Get Your Face Ripped Off

While it's tempting to take on a long-side trade here, I don't see a good reason.
By STEPHEN GUILFOYLE
Jun 11, 2021 | 10:45 AM EDT
Stocks quotes in this article: VRTX, ARWR, TAK

The bell had rung. Vertex Pharmaceuticals (VRTX) had closed at $216.77, up more than three bucks, up 1.5% for the day. Within seconds, the stock would go into an after-hours free-fall. News had broken that Vertex would abandon any further development of the firm's lead candidate for the treatment of alpha-1 antitrypsin deficiency, which is a rare genetic disease that impacts the liver's ability to make proteins normally.

Vertex reported Phase 2 clinical results for VX-864, and while compared to patients dosed with a placebo, patients treated with the candidate did see statistically significant increases in mean functional alpha-1 antitrypsin levels from a baseline. The results however, in the company's opinion, are not likely to lead to substantial patient benefit. Vertex had apparently discontinued the development of a similar candidate last autumn due to safety concerns. The firm will focus on other small molecule candidates, but is not close on anything.

Vertex's next candidate for the treatment of this liver disorder will not be tested on human beings until 2022, and any kind of mid-stage readouts could not at this point be expected for two to three years. Why this is key is that the firm has become quite profitable due to the success of its suite of treatments for cystic fibrosis, but clearly needs to diversify as sales growth has slowed. VX-864 was seen as the closest candidate in the firm's pipeline to doing just that.

The firm also co-released some positive looking early stage data with CRISPR Therapeutics (CRSP) for the treatment of sickle cell disease, but the failure to progress with VX-864 was the focus on Thursday night.

Alternatives

Traders will have by now noticed the pop in the shares of Arrowhead Pharmaceuticals (ARWR) , and Takeda Pharmaceuticals (TAK) . These two operations are working together on a late stage candidate meant to take on alpha-1 antitrypsin deficiency. There is hope for those suffering this malady.

Wall Street

I have noticed 15 sell-side analysts that have opined on Vertex since this news broke last night. Of the 15, seven are rated at five stars at Tip Ranks. Of those seven, six have reiterated "buy" (or their firm's equivalent) ratings, with an average target price of $290. Of those six the high target is $347 (Edward Tenthoff at Piper Sandler), and the low target would be $245 (Cory Kasimov at JP Morgan). There was one "Hold" rating. That was Morgan Stanley's Matthew Harrison who has a target price of $205.

The Chart

My first thought is... wow, that's one heck of a gap. Support that had been tested multiple times since last October had broken. Both the 50 day SMA and 21 day EMA are broken as potential short-term support after only being retaken this week.

While it is tempting to take on a long-side trade here, I don't see a good reason, other than the opinion of a few highly rated analysts who were already (except for Harrison) very wrong, for a rapid recovery. Yes, gaps do usually fill. My thinking, and this is just opinion... that Vertex is a prime candidate for Jim Cramer's "three day" rule. At least for the equity. See where this thing is trading on Monday or Tuesday. By then, you will either have a better entry point, or will have missed an opportunity. Neither outcome will get your face ripped off.

You could buy a $205 call expiring in a week for about $1.75. Something like that might be the play.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle had no position in the securities mentioned.

TAGS: Drug Approvals | Investing | Markets | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals

More from Investing

AeroVironment Could Resume Its Upward Flight Pattern

Bruce Kamich
Jun 28, 2022 8:13 AM EDT

The drone maker's charts suggest a higher stock price ahead of its latest quarterly earnings report after Tuesday's market close.

The Challenge of Sustained Momentum in an Illiquid Market

James "Rev Shark" DePorre
Jun 28, 2022 7:57 AM EDT

It would be a mistake to assume that the market recovery this time will be swift and easy.

Zero-Covid? NATO's China Challenge, Quarter-End Volume, Yields, Trading Chevron

Stephen Guilfoyle
Jun 28, 2022 7:23 AM EDT

There was a time when Covid vaccine news was headline material. Not now, though, and this news could matter.

Get the Facts, Not the Hype, Then Trade

Paul Price
Jun 28, 2022 7:00 AM EDT

Rather than waste time trying to predict when, or if, a recession is on the way, why not simply buy shares that appear quite undervalued? Here are two to start with.

What's the 'Pain Trade' Now?

Helene Meisler
Jun 28, 2022 6:00 AM EDT

Is it more rallying to suck more people in? Or is it a rollover that will spit out those 'Sentiment Tourists'? Let's take a look.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login